Open for inclusion

An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification

Cancer type: Solide tumores

Phase: II

Principal Investigator: Joensuu Heikki

Country: FI

Keywords: Helsinki, Finland

Status: Open for inclusion

Link to